- Conditions
- Breast Neoplasms
- Interventions
- Tamoxifen, Vorinostat, Pembrolizumab
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- San Francisco, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1057–1080
of 6,983
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Triple-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
- Interventions
- BET Bromodomain Inhibitor ZEN-3694, Binimetinib, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Galveston, Texas • Houston, Texas
- Conditions
- Breast Cancer
- Interventions
- etoposide, ifosfamide, topotecan hydrochloride, peripheral blood stem cell transplantation
- Drug · Procedure
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years to 64 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2001
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Triple Negative Breast Cancer, HER2-negative Breast Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Castrate Resistant Prostate Cancer, Pancreatic Ductal Adenocarcinoma, Head-and-neck Squamous Cell Carcinoma, Endometrial Cancer, Ovarian Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Urothelial Carcinoma
- Interventions
- DR-0202
- Drug
- Lead sponsor
- Dren Bio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 10
- States / cities
- Denver, Colorado • Orlando, Florida • Sarasota, Florida + 7 more
- Conditions
- Triple Negative Breast Cancer
- Interventions
- urine collection
- Other
- Lead sponsor
- George Washington University
- Other
- Eligibility
- 21 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Breast Cancer
- Interventions
- Positron Emission Mammography, Magnetic Resonance Imaging
- Procedure
- Lead sponsor
- Naviscan PET Systems
- Industry
- Eligibility
- 25 Years and older · Female only
- Enrollment
- 472 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 6
- States / cities
- Los Angeles, California • San Diego, California • Boca Raton, Florida + 3 more
- Conditions
- Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Urothelial Carcinoma, Pancreatic Adenocarcinoma, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms
- Interventions
- BMS-986340, BMS-936558-01, Docetaxel, Pumitamig
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 11
- States / cities
- Clovis, California • Los Angeles, California • Newport Beach, California + 6 more
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma
- Interventions
- Diagnostic Mammography, Resection, Ultrasound Imaging, Twinkling Marker Placement
- Procedure · Device
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Breast Cancer
- Interventions
- FFDM Plus DBT, FFDM Alone
- Device
- Lead sponsor
- Fujifilm Medical Systems USA, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 298 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Iowa City, Iowa • Rochester, New York + 2 more
- Conditions
- Breast Cancer
- Interventions
- 89Zr-Trastuzumab Human Dosimetry and Safety, HER2 Positive Lesion Detection and Safety
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Bone Pain in Stage I - III Breast Cancer
- Interventions
- Naproxen, Loratadine, Pegfilgrastim, Chemotherapy
- Drug · Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years · Female only
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 83
- States / cities
- Muscle Shoals, Alabama • Anaheim, California • Fullerton, California + 78 more
- Conditions
- Breast Cancer
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 945 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
- Interventions
- Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacogenomic Study, Pharmacological Study, Vismodegib
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Ann Arbor, Michigan • Detroit, Michigan
- Conditions
- Colorectal Cancer, Breast Cancer
- Interventions
- Mammography direct mail coupled with a financial incentive, Usual care, Colonoscopy direct mail coupled with a financial incentive
- Behavioral
- Lead sponsor
- Minnesota Department of Health
- Government
- Eligibility
- 50 Years to 74 Years
- Enrollment
- 138,554 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- Breast Cancer
- Interventions
- Intermittent Fasting
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 20 Years to 70 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Breast Cancer
- Interventions
- alvocidib, docetaxel
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2003
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Palmar-Plantar Erythrodysesthesia, Breast Cancer
- Interventions
- Cream, 0.1% Uracil Cream
- Drug
- Lead sponsor
- Nanometics (d.b.a. PHD Biosciences)
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Palm Springs, California • Evansville, Indiana + 3 more
- Conditions
- HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
- Interventions
- Aromatase Inhibition Therapy, Carboplatin, Cytology Specimen Collection Procedure, Docetaxel, Goserelin Acetate, Laboratory Biomarker Analysis, Pertuzumab, Quality-of-Life Assessment, Therapeutic Conventional Surgery, Trastuzumab, Whole Breast Irradiation
- Drug · Other · Biological + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 315 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 731
- States / cities
- Fairbanks, Alaska • Hot Springs, Arkansas • Anaheim, California + 466 more
- Conditions
- HER2 Positive Breast Cancer, Cardiovascular Abnormalities
- Interventions
- Carvedilol
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2025
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Breast Cancer, Mastectomy, Perfusion; Complications, Hemostasis
- Interventions
- PlasmaBlade 3.0S
- Device
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland
- Conditions
- Breast Cancer
- Interventions
- Inavolisib, Placebo, CDK4/6i, Letrozole
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 62
- States / cities
- Goodyear, Arizona • Phoenix, Arizona • Burbank, California + 50 more
- Conditions
- Triple Negative Breast Cancer, Residual Disease
- Interventions
- Niraparib, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Neoplasms, Invasive Breast Cancer, Estrogen-receptor-positive Breast Cancer, HER2-negative Breast Cancer
- Interventions
- (Z)-endoxifen, goserelin
- Drug
- Lead sponsor
- Atossa Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 11 more
- Conditions
- Small Cell Lung Cancer and Breast Cancer
- Interventions
- Satoreotide tetraxetan, Satoreotide trizoxetan
- Drug
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas